|Assessment Status||Rapid Review Complete|
|Indication||Rivaroxaban 10mg/day plus a P2Y12 inhibitor for stroke prevention due to NVAF in patients with renal impairment undergoing PCI with stent placement.|
|Rapid review commissioned||20/11/2017|
|Rapid review completed||21/11/2017|
|Rapid review outcome||Full Pharmacoeconomic Assessment Recommended|
A full pharmacoeconomic evaluation is not required as rivaroxaban 10mg is reimbursable under the Community Drug Schemes.